67Cu-SARTATE not checked
Clarity Pharmaceuticals Ltd · Cu-67 SARTATE · copper 67 SARTATE
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Main trialPhase 1/2
- “The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.”In the company’s words, NCT04023331 on ClinicalTrials.gov
- Other names
- Cu-67 SARTATE · copper 67 SARTATE
Other drugs for Neuroblastoma
- EB-DTNB-NKBeijing Biotech · Phase 1/2
- APG-115Ascentage Pharma Group Inc. · Phase 1/2
- LisaftoclaxAscentage Pharma Group Inc. · Phase 1/2
- EntrectinibRoche · Phase 1/2
- Zilovertamab vedotinMerck & Co. · Phase 1/2
- Allogenic NK cellsMarzieh Ebrahimi · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Terminated | 24 Jan 2025 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026